JP2017514867A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514867A5
JP2017514867A5 JP2016566786A JP2016566786A JP2017514867A5 JP 2017514867 A5 JP2017514867 A5 JP 2017514867A5 JP 2016566786 A JP2016566786 A JP 2016566786A JP 2016566786 A JP2016566786 A JP 2016566786A JP 2017514867 A5 JP2017514867 A5 JP 2017514867A5
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
heterocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514867A (ja
JP6479854B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059453 external-priority patent/WO2015169677A1/en
Publication of JP2017514867A publication Critical patent/JP2017514867A/ja
Publication of JP2017514867A5 publication Critical patent/JP2017514867A5/ja
Application granted granted Critical
Publication of JP6479854B2 publication Critical patent/JP6479854B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566786A 2014-05-07 2015-04-30 医薬組成物のためのスルホキシイミン置換キナゾリン Expired - Fee Related JP6479854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167373 2014-05-07
EP14167373.1 2014-05-07
PCT/EP2015/059453 WO2015169677A1 (en) 2014-05-07 2015-04-30 Sulfoximine substituted quinazolines for pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2017514867A JP2017514867A (ja) 2017-06-08
JP2017514867A5 true JP2017514867A5 (enExample) 2018-09-20
JP6479854B2 JP6479854B2 (ja) 2019-03-06

Family

ID=50639371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566786A Expired - Fee Related JP6479854B2 (ja) 2014-05-07 2015-04-30 医薬組成物のためのスルホキシイミン置換キナゾリン

Country Status (7)

Country Link
US (1) US10167296B2 (enExample)
EP (1) EP3140300B1 (enExample)
JP (1) JP6479854B2 (enExample)
AU (1) AU2015257917C1 (enExample)
CA (1) CA2944103A1 (enExample)
ES (1) ES2749186T3 (enExample)
WO (1) WO2015169677A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
JP4518378B2 (ja) 2001-10-29 2010-08-04 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング エネルギー恒常性および細胞小器官代謝の調節に関与するＭｎｋキナーゼ相同性タンパク質
GB0315587D0 (en) 2003-07-03 2003-08-13 Univ Dundee Anti-inflammatory assay and compounds
ES2611018T3 (es) 2004-04-08 2017-05-04 Dow Agrosciences Llc Sulfoximinas N-sustituidas insecticidas
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007104053A2 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2152672A1 (en) 2007-05-24 2010-02-17 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
UY32072A (es) * 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
JP5575274B2 (ja) * 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
MX2012009851A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US9170933B2 (en) * 2010-06-28 2015-10-27 International Business Machines Corporation Wear-level of cells/pages/sub-pages/blocks of a memory
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
HK1206723A1 (en) 2012-05-21 2016-01-15 Bayer Pharma Aktiengesellschaft Thienopyrimidines
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014048869A1 (en) * 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
EP2917185B1 (en) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
CA2899662A1 (en) * 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CA2914525C (en) * 2013-06-28 2021-07-27 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
CA2929742C (en) * 2013-12-04 2022-09-20 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions

Similar Documents

Publication Publication Date Title
ES3036123T3 (en) Heterocyclic rip1 kinase inhibitors
CA2903288C (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP7145931B2 (ja) 化合物の結晶多形、その製造方法及び用途
EP4013749B1 (en) Alkynyl quinazoline compounds
JP2016121196A5 (enExample)
JP2018515495A5 (enExample)
JP2016512823A5 (enExample)
AU2014234906B2 (en) Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
CN105934432A (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
MX2015004787A (es) Compuestos antiviricos para el virus sincitial respiratorio.
JP2016519165A5 (enExample)
AU2015335783B2 (en) Tricyclic atropisomer compounds
WO2016089060A2 (en) Heterocyclic derivatives and use thereof
JP2015508092A5 (enExample)
CN110776481B (zh) 一类双阳离子化合物及其制备方法和用途
JP2017527598A5 (enExample)
WO2017084640A1 (zh) 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
JP2019532067A5 (enExample)
WO2018133875A1 (zh) Jak酶抑制剂及其制备方法和用途
US20190202826A1 (en) Phosphotidylinositol 3-Kinase Inhibitors
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
JP2017514867A5 (enExample)
JP2020517676A5 (enExample)
WO2023160672A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity